Update: factors influencing heart rate variability-a narrative review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39165281/
In order to improve the quality of HRV studies and to ensure accurate interpretation, it is recommended that confounders be taken into account in future diagnostic measurements or measurements in...
This narrative review highlights factors influencing heart rate variability (HRV), categorizing them as non-influenceable physiological factors, diseases, lifestyle choices, and external elements, stressing the importance of considering these confounders in HRV interpretation.
Heart Failure: a Punch from the Gut
Source : https://pubmed.ncbi.nlm.nih.gov/38300390/
A growing field of research is focused on the effects of a "leaky gut" in the development of disease across organ systems. The leaky gut hypothesis centers on intestinal epithelial...
Targeting gut composition may significantly improve heart failure (HF) outcomes by addressing gut dysbiosis and epithelial barrier dysfunction, highlighting a crucial therapeutic avenue.
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction
Source : https://pubmed.ncbi.nlm.nih.gov/38588929/
In patients with AMI, the severity of left ventricular dysfunction and the presence of congestion was associated with worse outcomes. Empagliflozin reduced first and total HF hospitalizations across the range...
Empagliflozin reduced HF hospitalizations post-AMI, regardless of LVEF or congestion, with consistent safety. Severity of LVEF dysfunction and congestion correlated with worse outcomes.
Where Are We With Treatment and Prevention of Heart Failure in Patients Post-Myocardial Infarction
Source : https://pubmed.ncbi.nlm.nih.gov/38878010/
As a result of the widespread use of reperfusion therapies and secondary prevention over the last 30 years, there has been a dramatic reduction in the risk of mortality and...
Despite advances in reperfusion and secondary prevention, chronic heart failure (HF) remains common post-myocardial infarction (MI). Neurohormonal inhibition and emerging therapies aim to mitigate HF risk and myocardial damage.
The current best drug treatment for hypertensive heart failure with preserved ejection fraction
Source : https://pubmed.ncbi.nlm.nih.gov/37865559/
More than 90 % of patients developing heart failure (HF) have hypertension. The most frequent concomitant conditions are type-2 diabetes mellitus, obesity, atrial fibrillation, and coronary disease. HF outcome research...
Heart failure (HF) treatment involves antihypertensives and other drugs, regardless of left ventricular ejection fraction (LVEF). Focus on symptom management, signs, severity, and comorbid conditions.